So, as we’ve discussed over the past few days (check yesterday’s blog, if you want), the FDA approved Aduhelm, the monoclonal antibody that attaches to amyloid. The problem is that there is no clinical data demonstrating this will help alleviate the memory loss in Alzheimer’s patients- despite the FDA approval.
Continue reading Alzheimers- but not Aduhelm
We spoke about the Aduhelm fiasco about two weeks ago.
Continue reading Aduhelm controversy- part 2
While the Jewish summer started 17 days ago with the advent of the month of Tamuz, that’s not really why folks like me remember Tamuz.
Continue reading 17th of Tamuz
By now, you’ve heard all the hoopla surrounding our tax rates and tax system. Most of the ideas I’ve heard involve radical changes the way data is collected- which means, at least to me- that they won’t work- at least not for a while.
Continue reading How to fix our taxes
Now that I’ve got you incensed (you did read yesterday’s blog, right?), let’s discuss a little of the mechanics of the private equity industry. Which, even if your blood is not yet boiling, may cause you to need a trip to the emergency room when we are done.
Continue reading Carried Interest, Part 2
You already know that I consider TheDonald the most corrupt president (along with his administration) that America has endured since the days of Tricky Dick.
Continue reading Have your blood pressure meds ready…
Is it really the pandemic? Donald Trump’s Directive? Or HHS pressure (read as payment incentives, which are related to Donald’s directive)? [HHS kidney care payment protocol that began in 2021, a year later than promised, provided increased reimbursements for home dialysis]
Continue reading Dialysis at Home?
We keep hearing that Tesla has a full self-driving system and plenty of other vendors will be offering such concepts soon. Except – that’s not the facts.
Continue reading Tesla and Self-Driving Cars
Hmm. Is this good news or not?
The FDA (Food and Drug Administration) has just approved aducanumab (Aduhelm) for Alzheimer’s. Of course, if you are Biogen, this is great news. But, since the data is – how do I say this?- less than emphatic- will this really help patients?
Continue reading Hope or Chimera for Alzheimer’s Patients?